DB31656ApprovedVaccines
CX-051869 is a COVID-19 mRNA vaccine encoding the pre-fusion stabilized Spike glycoprotein (S) of the SARS-CoV-2 Omicron variant lineage LP.8.1. It is the active ingredient of the 2025-2026 formulation of...
- Primary indication
- CX-051869, as the active ingredient in the 2024-2025 formulation of Spikevax, is indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients ≥65 years...Curator reviewed
- First approval
- United States, 2025
- Also known as
- Spikevax (2025-2026 Formula)
- Code names
- CX-051869
Resolves to
Compound
Clinical / RWD
What you can answer from here — as of November 20, 2025
Which companies are running trials of CX-051869, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account